OpenAI acquires Orchestra Bio to advance AI drug development
OpenAI has acquired biotech startup Orchestra Bio and will integrate its team and technology into its life sciences research platform, Rosalind, expanding AI applications in drug development in an effort to accelerate the arrival of new therapies.
Read original article ↗
Related Articles
Broad access through consistent standards
How OpenAI works with distribution partners to uphold consistent safeguards, support responsible access, and clarify exp
Anthropic takes on Muse with Claude Duet, its new AI agent
Anthropic just announced an AI agent competitor to Meta's Muse and OpenAI's Dots: Claude Duet. The new agent, designed f
PHP Armageddon: OpenAI, Google’s Wiz find ancient holes, panicking the internet
This is the kind of security issue that was found and prevented by AI, but is also a high risk because of AI.
How AT&T is rethinking in-house legal work with OpenAI
AT&T is working with OpenAI to make legal knowledge easier to access. Learn how its LegalEdge team is rethinking intake